CDC Recommends 2nd COVID-19 Vaccine Dose for Seniors & Immunocompromised | CDC Newsroom

October 23, 2024 – The Centers for Disease Control and Prevention (CDC) today endorsed the recommendation from its Advisory Committee on Immunization Practices (ACIP) for an additional dose of the updated 2024-2025 COVID-19 vaccine for adults aged 65 years and older, as well as for individuals with moderately or severely compromised immune systems. This updated guidance builds on previous recommendations and aims to bolster protection against the virus, particularly for those at highest risk of severe illness. The CDC as well clarified that individuals who are moderately or severely immunocompromised may receive additional doses, determined through shared clinical decision-making with their healthcare provider.

The recommendation stems from ongoing monitoring of COVID-19’s impact and evolving understanding of vaccine effectiveness. As immunity from vaccination wanes over time and new variants emerge, maintaining up-to-date protection becomes increasingly essential, especially for vulnerable populations. The CDC’s decision acknowledges the continued circulation of COVID-19 throughout the year and the need for enhanced protection for those most susceptible to severe outcomes.

Who is Affected by the Updated Guidance?

This updated recommendation directly impacts two key groups: adults 65 years and older, and individuals with moderate to severe immunocompromise. Older adults are known to be at higher risk for severe COVID-19 illness, hospitalization, and death due to age-related decline in immune function. Immunocompromised individuals, whose immune systems are weakened by conditions like cancer, organ transplantation, or certain medications, may not mount a sufficient immune response to initial vaccination, necessitating additional doses. This includes people with type 1 and type 2 diabetes, those who are pregnant, and people undergoing cancer treatment, as noted in recent reporting from Prevention.com.

Understanding the Evidence and its Limitations

The ACIP’s recommendation is based on a review of available data on vaccine effectiveness, the severity of illness in different populations, and the current landscape of circulating COVID-19 variants. Although the specific data informing this particular recommendation isn’t detailed in the CDC’s release, it’s understood to be informed by ongoing surveillance efforts and clinical trials evaluating the performance of updated vaccines. It’s important to note that vaccine effectiveness isn’t static. it can vary depending on the variant in circulation, the time since vaccination, and individual factors like age and immune status. The CDC continues to monitor these factors closely.

What Does This Mean for Individuals?

For adults 65 and older, In other words they are now advised to receive a second dose of the 2024-2025 COVID-19 vaccine approximately six months after their first dose. For those with moderate to severe immunocompromise, the guidance allows for greater flexibility, with the number of doses determined in consultation with their healthcare provider. This shared clinical decision-making approach recognizes that individuals’ immune responses and risk factors can vary significantly. The CDC emphasizes that staying up to date on vaccinations remains a crucial step in protecting oneself and reducing the risk of severe illness, hospitalization, and long-term health consequences like Long COVID. You can find more information on staying up to date on COVID-19 vaccines at the CDC’s website.

Putting Risk into Context

It’s crucial to understand that while COVID-19 continues to circulate, the risk of severe illness is significantly lower for vaccinated individuals compared to those who are unvaccinated. The CDC’s recommendation isn’t about eliminating risk entirely, but about mitigating it, particularly for those most vulnerable. The benefits of vaccination – reducing the likelihood of hospitalization, severe disease, and long-term health problems – continue to outweigh the risks of potential side effects. As the National Council on Aging points out, vaccination is a safe and effective way for older adults to protect themselves and their communities.

The Ongoing Public Health Response

The CDC’s updated recommendation is part of an ongoing effort to adapt to the evolving nature of the COVID-19 pandemic. The agency continues to monitor viral variants, track vaccine effectiveness, and refine its guidance based on the latest scientific evidence. This includes ongoing surveillance through various channels, including wastewater monitoring, genomic sequencing, and clinical data analysis. The CDC also works closely with state and local health departments to ensure that vaccines are readily available and accessible to all who need them.

What Comes Next: Monitoring and Future Updates

The CDC and ACIP will continue to evaluate the impact of these updated recommendations and monitor emerging data on vaccine effectiveness and variant evolution. Further adjustments to guidance may be necessary as the pandemic continues to unfold. Individuals are encouraged to stay informed about the latest recommendations from the CDC and their healthcare providers. The agency will provide updates as new information becomes available, ensuring that public health strategies remain aligned with the best available science.

The following statement is attributable to CDC Director Dr. Mandy Cohen:

“This vote allows people to create the best decisions possible to keep themselves and their loved ones safe from COVID-19. CDC will continue to educate the public on how and when to get their updated vaccinations so they can risk less severe illness and do more of what they love.”